📊 COCHW Key Takeaways
Investment Thesis
Envoy Medical is in critical financial distress with negative stockholders' equity of -$7.7M, indicating technical insolvency. The company is burning cash at an alarming rate (-$12.5M operating cash flow) while generating minimal revenue ($166K), demonstrating fundamental operational failure and inability to sustain operations without immediate capital intervention.
COCHW Strengths
- Maintains $3.6M cash position providing short-term liquidity runway
- Recent insider Form 4 filings (8 in last 90 days) suggest management engagement
- Modest capital expenditure ($7K) indicates discipline in avoiding additional capex drain
COCHW Risks
- Negative stockholders' equity of -$7.7M represents technical insolvency and existential solvency risk
- Severe operating losses (-$15.9M) with revenue declining 28.8% YoY indicates deteriorating core business
- Negative operating cash flow of -$12.5M with only $3.6M cash suggests runway of approximately 3 months at current burn rate
- Current ratio of 0.64x and quick ratio of 0.46x indicate acute liquidity crisis and inability to meet short-term obligations
- Liabilities exceed assets by $7.5M, creating structural insolvency
Key Metrics to Watch
- Cash balance and runway timeline - critical for going concern assessment
- Monthly operating cash burn rate and trajectory
- Revenue stabilization or decline acceleration - fundamental viability indicator
- Restructuring announcements or financing activities indicating recapitalization attempts
- Quarterly cash position trend to assess proximity to insolvency
COCHW Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
COCHW Profitability Ratios
COCHW vs Default Sector
How Envoy Medical, Inc. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
COCHW Balance Sheet & Liquidity
COCHW 5-Year Financial Trend
5-Year Trend Summary: Envoy Medical, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.54 indicates the company is currently unprofitable.
COCHW Growth Metrics (YoY)
COCHW Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $42.0K | -$3.9M | $-0.35 |
| Q2 2025 | $68.0K | -$3.9M | $-0.29 |
| Q1 2025 | $46.0K | -$5.0M | $-0.29 |
| Q3 2024 | $56.0K | $1.6M | $0.13 |
| Q2 2024 | $63.0K | -$3.9M | $-0.27 |
| Q1 2024 | $59.0K | -$6.3M | $-0.32 |
| Q3 2023 | $57.0K | -$1.2M | $-0.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
COCHW Capital Allocation
COCHW SEC Filings
Access official SEC EDGAR filings for Envoy Medical, Inc. (CIK: 0001840877)
📋 Recent SEC Filings
❓ Frequently Asked Questions about COCHW
What is the AI rating for COCHW?
Envoy Medical, Inc. (COCHW) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are COCHW's key strengths?
Maintains $3.6M cash position providing short-term liquidity runway. Recent insider Form 4 filings (8 in last 90 days) suggest management engagement.
What are the risks of investing in COCHW?
Negative stockholders' equity of -$7.7M represents technical insolvency and existential solvency risk. Severe operating losses (-$15.9M) with revenue declining 28.8% YoY indicates deteriorating core business.
What is COCHW's revenue and growth?
Envoy Medical, Inc. reported revenue of $166.0K.
Does COCHW pay dividends?
Envoy Medical, Inc. pays dividends, with $1.8M distributed to shareholders in the trailing twelve months.
Where can I find COCHW SEC filings?
Official SEC filings for Envoy Medical, Inc. (CIK: 0001840877) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is COCHW's EPS?
Envoy Medical, Inc. has a diluted EPS of $-0.97.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.